Referenser
18. Lauenroth-Mai E, et al. Efficacy and tolerability of RTV-boosted atazanavir combined with tenofovirin patients with dyslipidaemia on anti retroviral therapy. 7th ICDT, Glasgow, United Kingdom, 2004. Poster abstract #P178.
19. Lakka HM, et al. The Metabolic Syndrome and CV disease mortality in middle-aged men. JAMA 2002; 288 (21) : 2709-16.
20. Gazzaruso C, et al. Hypertension among HIV patients : prevalence and relationships to insulin resistance andmetabolic syndrome. J Hypertens 2003;21:1377-82.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. “Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)”. JAMA 2001;19:2486-2497.
22. Jericó C, et al. Metabolic syndrome among HIV infected patients. Prevalence, characteristics, and related factors. Diabetes Care 2005; 28: 132-37.
23. Iloeje U, et al. Risk of metabolic syndrome (metsyn) among highly-treatment experienced HIV infected patients – 48 week results from BMS study AI 424045. XV International AIDS Conference, Bangkok, Thailand, 2004. Abstract #5957.
24. O'Brien ME. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34:407-14.
25. Tramarin A, et al. Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Quality of Life Research 2004; 13: 243-250.
26. O’Brien ME, Clark RA, Besch L, Myers L, Kissinger P. Patterns and Correlates of Discontinuation of the Initial HAART regimen in an Urban Outpatient Cohort. J Acquir Immune Defic Syndr 2003; 34: 407-414.
27. Berk PD, et al. Bilirubin metabolism and the hyperbilirubinemias. In Braunwald E et al, Eds. Harrison’s principles of internal medicine. 15th ed. New York 2001: 1715-20.
28. Zucker SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001;98:12671-76.
29. Witek J, et al. Safety of atazanavir (ATV) and atazanavir/ritonavir (ATV/r) in subjects co-infected with HIV and hepatitis B and/or C: 1100 subject-years of treatment exposure. Abstract presented at IAC, Toronto, Canada, 2006.
30. Atazanavir Briefing Document, May 2003. Available online at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1011Bristol-MyersSquibb-Atazanavir.pdf. Bristol-Myers Squibb Company, Princeton, NJ 08543, pp 38.
31. Badaro R, DeJesus E, Lazzarin A. Atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs lopinavir/ritonavir (LPV/RTV) in patients with multiple virologic failures: 24-week results from BMS AI424-45. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13–16, 2003; Paris, France.
32. Gibbons S, et al. Poster 4.1 PK and Pharmacodynamics. 10th European AIDS Conference/EACS, November 17–20, 2005, Dublin, Ireland.
33. Se respektive SPC på www.fass.se
34. Moyle G, et al. The asserting patients’ preferred treatments (APPT-1) study. Int J of STD and AIDS 2003; 14 (Suppl. 1): 34-36.